Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / COM
-
Shares outstanding
-
63.6M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
48.4M
-
Shares change
-
+426K
-
Total reported value, excl. options
-
$557M
-
Value change
-
+$5.26M
-
Put/Call ratio
-
0.05
-
Number of buys
-
49
-
Number of sells
-
-38
-
Price
-
$11.52
Significant Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) as of Q1 2022
113 filings reported holding RYTM - RHYTHM PHARMACEUTICALS, INC. - COM as of Q1 2022.
RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.4M shares
of 63.6M outstanding shares and own 76.08% of the company stock.
Largest 10 shareholders include PRIMECAP MANAGEMENT CO/CA/ (6.29M shares), FEDERATED HERMES, INC. (5.07M shares), NEA Management Company, LLC (4.91M shares), RA CAPITAL MANAGEMENT, L.P. (4.87M shares), BAKER BROS. ADVISORS LP (4.13M shares), GOLDMAN SACHS GROUP INC (3.34M shares), BlackRock Inc. (3.28M shares), JANUS HENDERSON GROUP PLC (2.95M shares), VANGUARD GROUP INC (2.26M shares), and FRANKLIN RESOURCES INC (1.78M shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.